menu
    • menu
    [{"orgOrder":0,"company":"Cobra Biologics","sponsor":"CombiGene","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"CG01","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cobra Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cobra Biologics \/ CombiGene","highestDevelopmentStatusID":"1","companyTruncated":"Cobra Biologics \/ CombiGene"},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cobra Biologics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Cobra Biologics \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Cobra Biologics \/ AstraZeneca"},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"Karolinska Institutet","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"DNA Vaccine","moa":"Amyloid-beta protein","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cobra Biologics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cobra Biologics \/ Karolinska Institutet","highestDevelopmentStatusID":"4","companyTruncated":"Cobra Biologics \/ Karolinska Institutet"},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"CG01","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Cobra Biologics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cobra Biologics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Cobra Biologics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Cobra Biologics

    Menu

    Cobra Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Cobra Biologics

    United Kingdom arrow
    Interphex
    Not Confirmed

    Cobra Biologics

    United Kingdom arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : CG01

    Therapeutic Area : Neurology

    Study Phase : Undisclosed

    Sponsor : CombiGene

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Cobra Biologics Delivers Plasmids for CombiGene's Epilepsy Candidate

    Details : Cobra Biologics has successfully produced and supplied further two DNA plasmids for the production of CombiGene AB’s gene therapy drug candidate CG01, which is being developed for the treatment of drug-resistant focal epilepsy.

    Product Name : CG01

    Product Type : Cell and Gene therapy

    Upfront Cash : Undisclosed

    July 13, 2020

    Lead Product(s) : CG01

    Therapeutic Area : Neurology

    Highest Development Status : Undisclosed

    Sponsor : CombiGene

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Cobra Biologics

    United Kingdom arrow
    Interphex
    Not Confirmed

    Cobra Biologics

    United Kingdom arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : ChAdOx1 nCoV-19

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase II/ Phase III

    Sponsor : AstraZeneca

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Cobra Biologics Signs Supply Agreement with AstraZeneca for Manufacture of COVID-19 Vaccine Candidate

    Details : Cobra will provide Astrazenrca with GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19.

    Product Name : AZD1222

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    June 16, 2020

    Lead Product(s) : ChAdOx1 nCoV-19

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase II/ Phase III

    Sponsor : AstraZeneca

    Deal Size : Undisclosed

    Deal Type : Agreement

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Cobra Biologics

    United Kingdom arrow
    Interphex
    Not Confirmed

    Cobra Biologics

    United Kingdom arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : DNA Vaccine

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Preclinical

    Sponsor : Karolinska Institutet

    Deal Size : $3.2 million

    Deal Type : Funding

    DEALS_DEV arrow-down

    Cobra Biologics and the Karolinska Institutet collaborate to develop COVID-19 vaccine

    Details : The funding will leverage phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium to support global efforts tackling the pandemic.

    Product Name : Undisclosed

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    March 31, 2020

    Lead Product(s) : DNA Vaccine

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Preclinical

    Sponsor : Karolinska Institutet

    Deal Size : $3.2 million

    Deal Type : Funding

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Cobra Biologics

    United Kingdom arrow
    Interphex
    Not Confirmed

    Cobra Biologics

    United Kingdom arrow
    Interphex
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : CG01

    Therapeutic Area : Neurology

    Study Phase : Undisclosed

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Cobra Biologics successfully completes key milestone in CombiGene’s epilepsy project

    Details : Production method of plasmids developed and first plasmid produced for gene therapy drug candidate aimed at treating drug resistant focal epilepsy.

    Product Name : CG01

    Product Type : Cell and Gene therapy

    Upfront Cash : Inapplicable

    February 04, 2020

    Lead Product(s) : CG01

    Therapeutic Area : Neurology

    Highest Development Status : Undisclosed

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth